{
  "pmcid": "5584556",
  "sha256": "23be255a07908433b51e7726f6ceaeab6c3b150e37b403a13968e83af011da91",
  "timestamp_utc": "2025-11-09T22:47:09.924154+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.380701754385964,
    "reading_ease": 28.859912280701792,
    "word_count": 228
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on KRAS Mutations and Rectal Cancer Response to Chemoradiation Therapy"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In this randomised controlled trial, 148 stage II–III rectal cancer patients were enrolled."
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligibility criteria included histologically confirmed rectal cancer."
      },
      "Intervention": {
        "score": 1,
        "evidence": "Participants underwent pre-operative CRT followed by surgery."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to correlate specific KRAS mutations with rectal cancer response to neoadjuvant chemoradiation therapy (CRT) and explore the association with TP53 mutations."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcome was pathologic complete response (pCR) measured post-surgery."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and allocation concealment methods were not specified."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding details were not provided."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "In this randomised controlled trial, 148 stage II–III rectal cancer patients were enrolled."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Tumors with any KRAS mutation were less likely to achieve pCR compared to wildtype KRAS (p=0.006)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: Not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 10,
    "max_score": 25
  }
}